GSKH - ETF AI Analysis
Top Page
GSK plc ADRhedged (GSKH)
Rating:75Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains over the past year-to-date and recent months, indicating solid momentum.
Low Expense Ratio
The fund charges a relatively low fee, which helps investors keep more of their returns over time.
Focused Exposure to a Major Health Care Company
The ETF’s heavy weighting in a large, established health care company provides targeted exposure to a key player in the sector.
Negative Factors
Extreme Single-Stock Concentration
Nearly the entire portfolio is invested in one company, which greatly increases the risk if that stock performs poorly.
Sector Concentration in Health Care
Almost all assets are in the health care sector, so the fund is highly sensitive to downturns or regulatory changes affecting that industry.
Very Limited Geographic Diversification
With almost all exposure tied to the U.S. market, the ETF offers little protection if that market faces a broad decline.
GSKH vs. SPDR S&P 500 ETF (SPY)
AUM723.70K
RegionEurope
Expense Ratio0.19%
Beta0.27
IssuerADRhedged
Inception DateJan 07, 2025
Dividend Yield1.61%
Asset ClassEquity
Index TrackedGSK plc - Benchmark Price Return
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,209
30 Day Avg. Volume667
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
86.92Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GSKH Summary
GSKH is an ETF that tracks the GSK plc Benchmark Price Return index and focuses on the pharmaceutical segment of the healthcare sector. It mainly holds shares of GlaxoSmithKline (GSK), a large, well-known drug company involved in vaccines and medicines worldwide. Investors might consider GSKH if they want targeted exposure to a major pharmaceutical player, with some protection against currency swings because it uses a hedged ADR structure. However, this ETF is highly concentrated in one company and sector, so its price can move sharply with news about GSK or changes in the healthcare market.
How much will it cost me?The GSK plc ADRhedged ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it focuses on a specific niche in the pharmaceutical sector while offering currency hedging benefits.
What would affect this ETF?The GSKH ETF could benefit from positive trends in the pharmaceutical sector, such as advancements in drug development, regulatory approvals, and increased demand driven by aging populations and global health initiatives. However, it may face challenges from stricter regulations, patent expirations, or economic downturns that could impact healthcare spending. Additionally, its focus on the U.K. market and reliance on GlaxoSmithKline may expose it to risks tied to regional economic conditions or company-specific performance.
GSKH Top 10 Holdings
GSKH is essentially a one-stock story, with GlaxoSmithKline doing almost all the heavy lifting. The fund is heavily concentrated in U.K.-based pharma, so its fortunes rise and fall with GSK’s share price. Lately, GSK has been climbing steadily on the back of strong specialty medicine growth and upbeat guidance, giving the ETF a clear tailwind rather than a tug-of-war between winners and laggards. With such a focused bet on one European healthcare giant, investors are getting precision exposure rather than broad diversification.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| GlaxoSmithKline | 98.23% | $738.31K | $109.05B | 42.46% | 77 Outperform |
GSKH Technical Analysis
Negative
―
Price Trends
77.99
Negative
74.65
Negative
66.82
Positive
Market Momentum
-1.42
Positive
30.74
Neutral
17.40
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSKH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 78.04, equal to the 50-day MA of 77.99, and equal to the 200-day MA of 66.82, indicating a neutral trend. The MACD of -1.42 indicates Positive momentum. The RSI at 30.74 is Neutral, neither overbought nor oversold. The STOCH value of 17.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GSKH.
GSKH Peer Comparison
Comparison Results
Performance Comparison
GSKH
GSK plc ADRhedged
71.54
18.00
33.62%
HSBH
HSBC Holdings plc ADRhedged
―
―
―
NVOH
Novo Nordisk A/S (B Shares) ADRhedged
―
―
―
ARMH
Arm Holdings PLC ADRhedged
―
―
―
BPH
BP p.l.c. ADRhedged
―
―
―
SHEH
Shell plc ADRhedged
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents